会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明授权
    • Pyrrolopyrimidines and processes for their preparation
    • 吡咯并嘧啶及其制备方法
    • US6140317A
    • 2000-10-31
    • US117056
    • 1998-07-22
    • Peter TraxlerJorg FreiGuido Bold
    • Peter TraxlerJorg FreiGuido Bold
    • A61K31/00A61K31/505A61K31/519A61K31/529A61P17/00A61P17/06A61P35/00A61P35/02A61P43/00C07D487/04A01N43/00A61K31/50C07D239/00C07D491/00C07F5/02
    • C07D487/04
    • There are described compounds of formula I ##STR1## wherein R.sub.1 and R.sub.2 are as defined in the description, Q is heterocyclyl boned via a ring nitrogen atom and having the formula IA ##STR2## wherein R.sub.3 and R.sub.4 and m and n are as defined in the description, the ring marked A is a heterocyclyl having 5 to 9 ring atoms and having at least one saturated bond, it being possible for a further ring hetero atom selected from O and S to be present in addition to the bonding nitrogen atom, the ring system marked B is a free or benzo-, thieno-, furo-, pyrrolo- or dihydropyrrolo-fused carbocyclic ring having from 5 to 9 carbon atoms that is fused to the ring A and may be unsaturated, partially saturated or fully saturated, and the bond marked by a parallel dotted line between the ring systems marked A and B is either a single bond or a double bond, and a salt thereof where at least one salt-forming group is present. The compounds are inhibitors of protein kinases and have, for example, antitumour activity.
    • PCT No.PCT / EP97 / 00127 Sec。 371日期:1998年7月22日 102(e)日期1998年7月22日PCT 1997年1月13日PCT PCT。 公开号WO97 / 27199 日期:1997年7月31日描述式I化合物,其中R 1和R 2如说明书中所定义,Q是经由环氮原子并具有式IA的杂环基,其中R 3和R 4以及m和n如 描述中,标记为A的环是具有5至9个环原子并且具有至少一个饱和键的杂环基,除了键合氮原子之外,还可以存在另外选自O和S的环杂原子,所述环 标记为B的系统是具有5至9个碳原子的游离或苯并,噻吩并 - 二氢吡咯并 - 稠合的碳环,其与环A稠合并且可以是不饱和的,部分饱和的或完全饱和的,以及 标记为A和B的环状体系之间的平行虚线标记的键是单键或双键,以及其中存在至少一个成盐基团的盐。 这些化合物是蛋白激酶的抑制剂,并且具有例如抗肿瘤活性。